Zura Bio Limited (Nasdaq: ZURA) announced its financial results for the full year ended December 31, 2025, highlighting significant progress in its clinical programs and a strengthened financial position. The company reported cash and cash equivalents of $109.4 million as of December 31, 2025, down from $176.5 million in the previous year, primarily due to increased research and development expenses. Zura's R&D expenses rose to $42.1 million, reflecting ongoing investments in its Phase 2 clinical trials for tibulizumab, a bispecific antibody targeting both IL-17 and BAFF pathways, aimed at treating hidradenitis suppurativa (HS) and systemic sclerosis (SSc).

The company completed a public offering in February 2026, raising approximately $144 million, which is expected to support operations through at least the end of 2028. Zura's leadership emphasized the importance of this funding in advancing their clinical strategy and achieving upcoming milestones. The Phase 2 TibuSHIELD trial for HS is ongoing, with topline data expected in Q4 2026, while the TibuSURE trial for SSc anticipates data in the first half of 2027.

CEO Sandeep Kulkarni expressed confidence in the company's trajectory, stating, "2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and a disciplined focus on advancing our clinical strategy." The company is well-positioned to capitalize on its dual-pathway approach, which aims to address complex autoimmune diseases that are not fully managed by existing therapies. Zura's innovative strategy and robust pipeline present a compelling opportunity for investors as the company moves forward with its clinical development plans.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.